BioCryst Pharmaceuticals, Inc. $BCRX Shares Sold by Fox Run Management L.L.C.

Fox Run Management L.L.C. lowered its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 39.8% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 17,725 shares of the biotechnology company’s stock after selling 11,700 shares during the period. Fox Run Management L.L.C.’s holdings in BioCryst Pharmaceuticals were worth $159,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the company. Assenagon Asset Management S.A. raised its holdings in BioCryst Pharmaceuticals by 25,631.2% in the 2nd quarter. Assenagon Asset Management S.A. now owns 3,620,637 shares of the biotechnology company’s stock valued at $32,441,000 after acquiring an additional 3,606,566 shares during the last quarter. Doliver Advisors LP boosted its holdings in shares of BioCryst Pharmaceuticals by 269.1% during the second quarter. Doliver Advisors LP now owns 274,328 shares of the biotechnology company’s stock worth $2,458,000 after purchasing an additional 200,000 shares during the last quarter. Acadian Asset Management LLC grew its position in shares of BioCryst Pharmaceuticals by 244.1% in the first quarter. Acadian Asset Management LLC now owns 670,361 shares of the biotechnology company’s stock valued at $5,023,000 after purchasing an additional 475,564 shares during the period. Millennium Management LLC increased its stake in BioCryst Pharmaceuticals by 382.6% in the first quarter. Millennium Management LLC now owns 3,812,874 shares of the biotechnology company’s stock valued at $28,597,000 after purchasing an additional 3,022,769 shares during the last quarter. Finally, Strs Ohio purchased a new position in BioCryst Pharmaceuticals during the first quarter worth about $284,000. Institutional investors and hedge funds own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Stock Up 2.6%

Shares of BCRX stock opened at $7.08 on Friday. BioCryst Pharmaceuticals, Inc. has a fifty-two week low of $6.00 and a fifty-two week high of $11.31. The firm’s 50 day moving average price is $7.33 and its two-hundred day moving average price is $8.63. The stock has a market cap of $1.49 billion, a price-to-earnings ratio of -39.33 and a beta of 1.09.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings data on Monday, November 3rd. The biotechnology company reported $0.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.07 by ($0.01). The firm had revenue of $159.40 million for the quarter, compared to the consensus estimate of $162.91 million. The firm’s quarterly revenue was up 36.1% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.07) earnings per share. BioCryst Pharmaceuticals has set its FY 2025 guidance at EPS. On average, equities analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on BCRX shares. Evercore ISI reissued an “in-line” rating and issued a $8.00 price target on shares of BioCryst Pharmaceuticals in a research note on Wednesday, October 1st. Wall Street Zen raised shares of BioCryst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 26th. Citizens Jmp dropped their price target on shares of BioCryst Pharmaceuticals from $27.00 to $25.00 and set a “market outperform” rating for the company in a research report on Wednesday, November 5th. Needham & Company LLC decreased their price target on shares of BioCryst Pharmaceuticals from $20.00 to $18.00 and set a “buy” rating on the stock in a report on Tuesday, November 4th. Finally, Cantor Fitzgerald boosted their price objective on shares of BioCryst Pharmaceuticals from $24.00 to $26.00 and gave the company an “overweight” rating in a research note on Wednesday, October 15th. Ten investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $19.33.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.